Long-term survival of a non-small cell lung cancer patient with EGFR-mutated brain metastases: a case report.

ABSTRACT:

Background

Lung cancer is the leading cause of cancer-related death worldwide. Up to 85% of lung cancer is non-small cell lung cancer (NSCLC) and most patients present with advanced disease at first diagnosis. Targeted therapy plays an important role in the treatment of advanced NSCLC. Epidermal growth factor receptor (EGFR) mutation is a predictive marker of sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Patients with EGFR-mutated NSCLC are prone to developing central nervous system (CNS) metastasis and poor prognosis (4-6 months). Brain metastases (BMs) remain a tricky problem in NSCLC patients and impose a distinct challenge for clinicians.

Case description

This article details a patient with EGFR-mutated BMs accepting a series of treat

SUBMITTER: Wan Y 

PROVIDER: S-EPMC9834592 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature